SLS
SELLAS Life Sciences Group, Inc.Company Information
- Company Name
- SELLAS Life Sciences Group, Inc.
- CIK
- CIK0001390478
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- SLS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- SLS
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-11-19
- Last sale
- 2022-12-05
- Shares purchased (TTM)
- 113,400
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 73,415,183
- Shares outstanding
- 189,183,620
- Ownership
- 38.81%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 25.43%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 138 | 107 | 72 | 44 | 25 | 28 | 14 | 21 | 9 | 18 | 3 | 4 | ||||||
| Restricted Cash And Cash Equivalents At Carrying Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 4 | 3 | 5 | 4 | 3 | 2 | 3 | 3 | 3 | 1 | 1 | ||||||
| Assets Current | 143 | 111 | 75 | 49 | 29 | 32 | 16 | 24 | 12 | 22 | 3 | 5 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Goodwill | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Deposits Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 145 | 114 | 78 | 52 | 32 | 35 | 19 | 27 | 15 | 24 | 6 | 8 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 4 | 3 | 2 | 3 | 4 | 4 | 5 | 6 | 7 | 6 | 4 | ||||||
| Accrued Liabilities Current | 4 | 2 | 4 | 3 | 2 | 3 | 5 | 5 | 5 | 7 | 8 | 7 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | ||||||
| Liabilities Current | 8 | 6 | 7 | 6 | 6 | 7 | 10 | 11 | 12 | 14 | 14 | 12 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 8 | 7 | 7 | 6 | 6 | 7 | 10 | 11 | 12 | 15 | 14 | 12 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 431 | 391 | 346 | 313 | 287 | 282 | 258 | 257 | 237 | 236 | 209 | 205 | ||||||
| Retained Earnings Accumulated Deficit | -293 | -283 | -275 | -267 | -261 | -254 | -248 | -241 | -234 | -227 | -217 | -209 | ||||||
| Stockholders Equity | 138 | 107 | 71 | 46 | 26 | 28 | 9 | 16 | 3 | 10 | -8 | -4 | ||||||
| Liabilities And Stockholders Equity | 145 | 114 | 78 | 52 | 32 | 35 | 19 | 27 | 15 | 24 | 6 | 8 | ||||||
| Series A Preferred Stock | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | - | - | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | ||||||
| Common Stock Shares Issued | 202 | 181 | 153 | 125 | 100 | 91 | 74 | 64 | 58 | 56 | 32 | 28 | ||||||
| Shares Outstanding | 202 | 181 | 153 | 125 | 100 | 91 | 74 | 64 | 58 | 56 | 32 | 28 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSELLAS Life Sciences Group, Inc. (SLS) — SEC Financial Statements & Analysis
SELLAS Life Sciences Group, Inc. (SLS) is a pharmaceutical preparations company, incorporated in DE. SELLAS Life Sciences Group, Inc. trades on Nasdaq as: SLS. SELLAS Life Sciences Group, Inc. (SLS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, SELLAS Life Sciences Group, Inc. carries a market cap of $2.79B, a P/E ratio of -86.02x, a P/B ratio of 20.28x, an enterprise value of $2.65B, and an EV/EBITDA multiple of -75.35x. On profitability, it posts a Return on Equity (ROE) of -39.63% and a Return on Assets (ROA) of -36.54%. Per share, it reports EPS of $-0.17, diluted EPS of $-0.17, free cash flow per share of $-0.15, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 23.62% year-over-year, and EPS growth of -35.60% year-over-year. On the balance sheet, it maintains a current ratio of 18.83x, a quick ratio of 18.29x, working capital of $134.94M, a debt-to-equity ratio of 0.06x, a debt ratio of 0.05, an interest coverage ratio of -12.77x, free cash flow of $-28.42M (TTM), and net debt of $-138.44M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.79B
- P/E TTM
- -86.02x
- EPS TTM
- $-0.17
- P/B TTM
- 20.28x
- ROE TTM
- -39.63%
- ROA TTM
- -36.54%
- Debt To Equity
- 0.06x
- Free Cash Flow TTM
- $-28.42M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is SELLAS Life Sciences Group, Inc. in?
SELLAS Life Sciences Group, Inc. (SLS) operates in the Pharmaceutical Preparations industry.
What exchange does SLS trade on?
SELLAS Life Sciences Group, Inc. (SLS) trades on the Nasdaq.
Where is SELLAS Life Sciences Group, Inc. incorporated?
SELLAS Life Sciences Group, Inc. is incorporated in DE.
When was SELLAS Life Sciences Group, Inc. (SLS)'s most recent SEC filing?
SELLAS Life Sciences Group, Inc. (SLS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is SLS's market cap?
SELLAS Life Sciences Group, Inc. (SLS) has a market capitalization of $2.79B as of 2026-06-30.
What is SLS's EPS (earnings per share)?
SELLAS Life Sciences Group, Inc. (SLS)'s trailing twelve month EPS is $-0.17 as of 2026-06-30.
What is SLS's ROE (return on equity)?
SELLAS Life Sciences Group, Inc. (SLS)'s trailing twelve month Return on Equity (ROE) is -39.63% as of 2026-06-30.
What is SLS's ROA (return on assets)?
SELLAS Life Sciences Group, Inc. (SLS)'s trailing twelve month Return on Assets (ROA) is -36.54% as of 2026-06-30.
What is SLS's EV/EBITDA?
SELLAS Life Sciences Group, Inc. (SLS)'s trailing twelve month EV/EBITDA is -75.35x as of 2026-06-30.